XRTX [NASD]
XORTX Therapeutics Inc.
Index- P/E- EPS (ttm)-0.44 Insider Own5.15% Shs Outstand12.37M Perf Week-10.26%
Market Cap24.50M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float12.29M Perf Month-28.21%
Income-1.70M PEG- EPS next Q- Inst Own8.16% Short Float0.16% Perf Quarter-6.67%
Sales- P/S- EPS this Y13.00% Inst Trans- Short Ratio0.10 Perf Half Y-48.72%
Book/sh1.35 P/B1.04 EPS next Y- ROA-14.50% Target Price- Perf Year-13.21%
Cash/sh1.08 P/C1.30 EPS next 5Y- ROE-34.30% 52W Range0.96 - 8.19 Perf YTD-31.71%
Dividend- P/FCF- EPS past 5Y10.90% ROI- 52W High-82.90% Beta0.36
Dividend %- Quick Ratio28.80 Sales past 5Y- Gross Margin- 52W Low45.60% ATR0.19
Employees- Current Ratio28.80 Sales Q/Q- Oper. Margin- RSI (14)41.49 Volatility6.03% 14.49%
OptionableNo Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.13 Prev Close1.47
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume199.20K Price1.40
Recom- SMA20-11.28% SMA50-14.94% SMA200-46.05% Volume25,333 Change-4.76%
May-05-22 07:00AM  
May-03-22 07:00AM  
Apr-20-22 07:00AM  
Apr-12-22 07:00AM  
Apr-07-22 07:00AM  
Mar-31-22 07:00AM  
Mar-23-22 07:00AM  
Mar-14-22 07:00AM  
Jan-31-22 07:00AM  
Jan-20-22 07:00AM  
Jan-12-22 08:30AM  
08:30AM  
Jan-10-22 07:00AM  
Dec-22-21 08:30AM  
Dec-21-21 06:00PM  
07:00AM  
Dec-10-21 07:01AM  
Dec-09-21 11:53AM  
09:30AM  
08:04AM  
Dec-02-21 07:00AM  
Nov-23-21 07:00AM  
Nov-15-21 08:00AM  
Nov-09-21 07:00AM  
Nov-05-21 08:11AM  
Nov-04-21 02:49PM  
08:21AM  
Nov-02-21 06:13PM  
Oct-15-21 05:38PM  
Oct-14-21 05:30PM  
07:00AM  
XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, hypertension, insulin resistance, and diabetic nephropathy. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is headquartered in Vancouver, Canada.